CAMP4 Therapeutics Corporation (CAMP) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseZacks Investment Research • Thursday
CAMP4 Therapeutics Receives Clinical Trial Application Approval for Phase 1/2 Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder in the European UnionGlobeNewsWire • Tuesday
CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related DisorderGlobeNewsWire • 09/10/26
CAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 2026GlobeNewsWire • 09/08/26
CAMP4 Therapeutics Corporation (CAMP) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/13/26
CAMP4 Therapeutics Announces Second Closing of $100 Million Private PlacementGlobeNewsWire • 08/04/26
CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related DisorderGlobeNewsWire • 07/27/26
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 07/17/26
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 06/19/26
New Analysis Strengthens Mercator Gold System and Confirms High-Grade BIF ContinuityGlobeNewsWire • 06/08/26
CAMP4 Therapeutics to Present New Preclinical Data Demonstrating CMP-002 Improves Seizure Threshold and Severity in a Model of SYNGAP1-Related DisorderGlobeNewsWire • 05/14/26
CAMP4 Therapeutics Corporation (CAMP) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/08/26
CAMP4 Therapeutics Preprints Pioneering Study on Regulatory RNA Profiling and Gene UpregulationGlobeNewsWire • 04/28/26
Camp4 Therapeutics Corporation (CAMP) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/15/26